Metastatic Cancer Clinical Trial
Official title:
A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer
in the laboratory may help doctors learn more about how this treatment is used by the body.
PURPOSE: The purpose of this study is to evaluate the feasibility of using a microdialysis
catheter to see what effect temsirolimus has on various biological substances associated with
brain tumors over time.
OBJECTIVES:
Primary
- Determine the feasibility of using a microdialysis catheter with a high cut-off membrane
to perform neuropharmacodynamics (nPD) assessment of targeted therapy with a mammalian
target of rapamycin (mTOR) inhibitor, where nPD is defined as changes in intracerebral
levels of vascular endothelial growth factor (VEGF), interleukin-1ß (IL-1ß), and other
cytokines.
Secondary
- Assess the relationship between temsirolimus dose and changes in intracerebral levels of
VEGF, IL-1ß, and other cytokines.
- Compare changes in intracerebral cytokine levels to changes in systemic cytokine levels.
- Assess the relationship between the degree of microvascular proliferation and the tensin
homologue deleted on chromosome 10 (PTEN) status in tumor tissue.
- Assess the relationship between changes in intracerebral cytokine levels after treatment
with temsirolimus.
OUTLINE: Two cohorts of 6 patients will be enrolled in this study. All patients undergo
debulking craniotomy or stereotactic biopsy and a placement of a intracerebral CMA 71
microdialysis (ICMD) catheter. Patients then are assigned to 1 of 2 treatment cohorts.
- Cohort 1: Patients do not receive temsirolimus. Dialysate samples will be collected at
regular intervals during the 96 hours following placement of the catheter as well as
serial blood samples to measure levels of cytokines, chemokines and growth factors that
occur after neurosurgery.
- Cohort 2: Beginning 48 hours after surgery, patients receive a single 200 mg dose of
temsirolimus IV. Dialysate samples will be collected at regular intervals during the 96
hours following placement of the catheter as well as serial blood samples to measure
levels of cytokines, chemokines and growth factors that occur after neurosurgery. Plasma
levels of temsirolimus and sirolimus will also be measured from the serial blood
samples.
After completion of study therapy and removal of ICMD catheter, patients are followed for 30
days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
| Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
| Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
| Not yet recruiting |
NCT03058809 -
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
| Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
| Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
| Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
| Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |